Multiple Sclerosis News Today

4 days ago | multiplesclerosisnewstoday.com | Margarida Maia

Almost two years of treatment with fenebrutinib — an investigational oral tablet for multiple sclerosis (MS) — helped patients with relapsing forms of the disease remain nearly free of relapses and disability progression. That’s according to new data from the open-label extension of FENopta (NCT05119569), a Phase 2 clinical trial that tested fenebrutinib against a placebo, both taken twice daily for three months, among people with relapsing-remitting MS or active secondary progressive MS.

5 days ago | multiplesclerosisnewstoday.com | Marisa Wexler

Pro-inflammatory signaling molecules that have been implicated in multiple sclerosis (MS) cause problems with the growth and development of myelin-making cells in the brain, according to a study done in cell models. The findings may have implications for treating MS, as promoting the growth of myelin-making cells could be a strategy for therapeutic approaches, the researchers said.

1 week ago | multiplesclerosisnewstoday.com | Marisa Wexler

People who experience adversity during childhood, such as abuse or neglect, may be at increased risk of multiple sclerosis (MS) and other autoimmune diseases, but available data that supports this association is generally low quality, a study reports. “Drawing concrete treatment recommendations is premature, given the low certainty of the findings,” wrote the researchers wrote, who emphasized a need for more studies to explore this potential association.

1 week ago | multiplesclerosisnewstoday.com | Margarida Maia

Half of multiple sclerosis (MS) patients in the U.K. who work have compromised their health by staying in jobs that didn’t fully support their MS needs, and nearly a third are in roles below their skill levels. That’s according to “No compromises: supporting people with MS to thrive in and out of work,” a joint report from the Work Foundation at Lancaster University and the MS Society UK. It was based on an online survey of 1,125 patients undertaken in 2024.

1 week ago | multiplesclerosisnewstoday.com | Steve Bryson

Clemastine fumarate, an antihistamine, boosted disease progression by more than five times in adults with progressive multiple sclerosis (MS), according to data from a Phase 1/2 trial. “Likely nobody in the MS field, us included, knew about this potential [clemastine] toxicity until we collected the data presented here,” the researchers wrote.